These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 9326409

  • 1. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI.
    Transplantation; 1997 Sep 27; 64(6):848-52. PubMed ID: 9326409
    [Abstract] [Full Text] [Related]

  • 2. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb 27; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

  • 3. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA, Andersen HK, Hamilton-Dutoit SJ.
    Transplantation; 1999 May 15; 67(9):1209-14. PubMed ID: 10342310
    [Abstract] [Full Text] [Related]

  • 4. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.
    Transplantation; 1998 Dec 27; 66(12):1604-11. PubMed ID: 9884246
    [Abstract] [Full Text] [Related]

  • 5. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T, Zwick DL, Rothberg PG, Warady BA.
    Pediatr Nephrol; 1999 Nov 27; 13(9):748-54. PubMed ID: 10603113
    [Abstract] [Full Text] [Related]

  • 6. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH.
    Transplantation; 1998 Dec 27; 66(12):1780-6. PubMed ID: 9884276
    [Abstract] [Full Text] [Related]

  • 7. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 27; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 8. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 9. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients.
    Keay S, Oldach D, Wiland A, Klassen D, Schweitzer E, Abruzzo LV, Kumar D, Bartlett S.
    Clin Infect Dis; 1998 Mar 27; 26(3):596-600. PubMed ID: 9524829
    [Abstract] [Full Text] [Related]

  • 10. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA.
    Transplantation; 1993 Jul 27; 56(1):88-96. PubMed ID: 8333073
    [Abstract] [Full Text] [Related]

  • 11. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG.
    J Heart Lung Transplant; 1995 Jul 27; 14(2):214-21. PubMed ID: 7779838
    [Abstract] [Full Text] [Related]

  • 12. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.
    Transplantation; 1998 Oct 27; 66(8):1047-52. PubMed ID: 9808490
    [Abstract] [Full Text] [Related]

  • 13. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 14. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 15. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
    Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR.
    J Heart Lung Transplant; 2002 May 27; 21(5):547-54. PubMed ID: 11983544
    [Abstract] [Full Text] [Related]

  • 16. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, Levi D, Nery JR, Cirocco RE, Gelman B, Ruiz P, Tzakis AG.
    Transplantation; 2002 Oct 15; 74(7):1000-6. PubMed ID: 12394845
    [Abstract] [Full Text] [Related]

  • 17. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M, Husain S, Famure O, Li Y, Kim SJ.
    Prog Transplant; 2019 Jun 15; 29(2):185-193. PubMed ID: 30845885
    [Abstract] [Full Text] [Related]

  • 18. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF.
    J Pediatr; 1997 Jul 15; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A, Hébert D, Davies HD, Humar A, Stephens D, O'Doherty B, Allen U.
    Transplantation; 2006 Mar 27; 81(6):856-61. PubMed ID: 16570008
    [Abstract] [Full Text] [Related]

  • 20. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks.
    Abu-Elmagd KM, Mazariegos G, Costa G, Soltys K, Bond G, Sindhi R, Green M, Jaffe R, Wu T, Koritsky D, Matarese L, Schuster B, Martin L, Dvorchik I, Nalesnik MA.
    Transplantation; 2009 Oct 15; 88(7):926-34. PubMed ID: 19935465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.